These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 24763532)

  • 1. The pathogenic potential of autoreactive antibodies in rheumatoid arthritis.
    Bax M; Huizinga TW; Toes RE
    Semin Immunopathol; 2014 May; 36(3):313-25. PubMed ID: 24763532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From Rheumatoid Factor to Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies for Diagnosis and Prognosis Prediction in Patients with Rheumatoid Arthritis.
    Wu CY; Yang HY; Luo SF; Lai JH
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases.
    Pecani A; Alessandri C; Spinelli FR; Priori R; Riccieri V; Di Franco M; Ceccarelli F; Colasanti T; Pendolino M; Mancini R; Truglia S; Barbati C; Vomero M; Sabatinelli D; Morello F; Valesini G; Conti F
    Arthritis Res Ther; 2016 Nov; 18(1):276. PubMed ID: 27887639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
    Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
    Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.
    Shi J; Knevel R; Suwannalai P; van der Linden MP; Janssen GM; van Veelen PA; Levarht NE; van der Helm-van Mil AH; Cerami A; Huizinga TW; Toes RE; Trouw LA
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17372-7. PubMed ID: 21987802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis.
    de Brito Rocha S; Baldo DC; Andrade LEC
    Adv Rheumatol; 2019 Jan; 59(1):2. PubMed ID: 30657101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls.
    Koppejan H; Trouw LA; Sokolove J; Lahey LJ; Huizinga TJ; Smolik IA; Robinson DB; El-Gabalawy HS; Toes RE; Hitchon CA
    Arthritis Rheumatol; 2016 Sep; 68(9):2090-8. PubMed ID: 26946484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology.
    Volkov M; van Schie KA; van der Woude D
    Immunol Rev; 2020 Mar; 294(1):148-163. PubMed ID: 31845355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between B cells and neutrophils in rheumatoid arthritis.
    Karmakar U; Vermeren S
    Immunology; 2021 Dec; 164(4):689-700. PubMed ID: 34478165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons.
    Alivernini S; Galeazzi M; Peleg H; Tolusso B; Gremese E; Ferraccioli G; Naparstek Y
    Autoimmun Rev; 2017 Nov; 16(11):1096-1102. PubMed ID: 28899798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss.
    Krishnamurthy A; Joshua V; Haj Hensvold A; Jin T; Sun M; Vivar N; Ytterberg AJ; Engström M; Fernandes-Cerqueira C; Amara K; Magnusson M; Wigerblad G; Kato J; Jiménez-Andrade JM; Tyson K; Rapecki S; Lundberg K; Catrina SB; Jakobsson PJ; Svensson C; Malmström V; Klareskog L; Wähämaa H; Catrina AI
    Ann Rheum Dis; 2016 Apr; 75(4):721-9. PubMed ID: 26612338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Hierarchies of Anti-Modified Protein Autoantibody Reactivities in Rheumatoid Arthritis.
    Sahlström P; Hansson M; Steen J; Amara K; Titcombe PJ; Forsström B; Stålesen R; Israelsson L; Piccoli L; Lundberg K; Klareskog L; Mueller DL; Catrina AI; Skriner K; Malmström V; Grönwall C
    Arthritis Rheumatol; 2020 Oct; 72(10):1643-1657. PubMed ID: 32501655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies.
    Reed E; Jiang X; Kharlamova N; Ytterberg AJ; Catrina AI; Israelsson L; Mathsson-Alm L; Hansson M; Alfredsson L; Rönnelid J; Lundberg K
    Arthritis Res Ther; 2016 May; 18(1):96. PubMed ID: 27145822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients.
    van Delft MAM; Verheul MK; Burgers LE; Derksen VFAM; van der Helm-van Mil AHM; van der Woude D; Huizinga TWJ; Toes REM; Trouw LA
    Arthritis Res Ther; 2017 Aug; 19(1):190. PubMed ID: 28810902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis.
    Konig MF; Giles JT; Nigrovic PA; Andrade F
    Ann Rheum Dis; 2016 Nov; 75(11):2022-2028. PubMed ID: 26865600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals.
    Verheul MK; Böhringer S; van Delft MAM; Jones JD; Rigby WFC; Gan RW; Holers VM; Edison JD; Deane KD; Janssen KMJ; Westra J; Brink M; Rantapää-Dahlqvist S; Huizinga TWJ; van der Helm-van Mil AHM; van der Woude D; Toes REM; Trouw LA
    Arthritis Rheumatol; 2018 Nov; 70(11):1721-1731. PubMed ID: 29781231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint.
    Ossipova E; Cerqueira CF; Reed E; Kharlamova N; Israelsson L; Holmdahl R; Nandakumar KS; Engström M; Harre U; Schett G; Catrina AI; Malmström V; Sommarin Y; Klareskog L; Jakobsson PJ; Lundberg K
    Arthritis Res Ther; 2014 Aug; 16(4):R167. PubMed ID: 25112157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies in inflammatory arthritis.
    Conigliaro P; Chimenti MS; Triggianese P; Sunzini F; Novelli L; Perricone C; Perricone R
    Autoimmun Rev; 2016 Jul; 15(7):673-83. PubMed ID: 26970491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox-Mediated Carbamylation As a Hapten Model Applied to the Origin of Antibodies to Modified Proteins in Rheumatoid Arthritis.
    Trejo-Zambrano MI; Gómez-Bañuelos E; Andrade F
    Antioxid Redox Signal; 2022 Mar; 36(7-9):389-409. PubMed ID: 33906423
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.